PLA2G2D: A Promising Drug Target for Platelet Function and Clot Prevention

Target Name: PLA2G2D

NCBI ID: G26279

PLA2G2D

PLA2G2D: A Promising Drug Target for Platelet Function and Clot Prevention

PLA2G2D, also known as sPLA2S, is a protein that is expressed in the endothelial cells of the body. It is a key regulator of platelet function and plays a role in the development and maintenance of blood clots. Despite its importance, PLA2G2D has remained a relatively unstudied protein, and there is limited research on its potential drug targets or biomarkers.

PLA2G2D is a member of the PLA2 family, which includes several other proteins that are involved in platelet function, such as PLA2 and PLA2-galactosylation. PLA2G2D is a protein composed of a single polypeptide chain, which is approximately 120 amino acids in length. PLA2G2D is located on the inside of the cell membrane, close to the phospholipid molecular layer of the cell membrane.

The main function of PLA2G2D is to regulate platelet function. Platelets play an important role in the blood clotting process. When blood vessels are damaged, platelets gather at the wound and form thrombi to stop bleeding. PLA2G2D is a key regulator of platelet aggregation and thrombosis.

Pharmacological research on PLA2G2D mainly focuses on its use as a drug target. Currently, there are several studies exploring the role of PLA2G2D in drug screening and treatment of platelet aggregation disorders.

First, PLA2G2D is used as a potential drug target to treat platelet aggregation disorders. Disorders of platelet aggregation include thrombocytopenia and platelet hyperaggregation. These diseases cause a decrease in platelets, making it harder for blood to flow, thereby increasing the risk of blood clots.

Secondly, PLA2G2D is also used as a potential drug target for the treatment of atherosclerosis. Atherosclerosis is a cardiovascular disease that causes the buildup of plaque in the lining of blood vessel walls. These plaques can narrow the blood vessel lumen and reduce blood flow

Protein Name: Phospholipase A2 Group IID

Functions: Secretory calcium-dependent phospholipase A2 that primarily targets extracellular lipids, exerting anti-inflammatory and immunosuppressive functions (PubMed:10455175, PubMed:10681567). Hydrolyzes the ester bond of the fatty acyl group attached at sn-2 position of phospholipids (phospholipase A2 activity) with preference for phosphatidylethanolamines and phosphatidylglycerols over phosphatidylcholines (PubMed:10455175). In draining lymph nodes, selectively hydrolyzes diacyl and alkenyl forms of phosphatidylethanolamines, releasing omega-3 polyunsaturated fatty acids (PUFAs) such as eicosapentaenoate and docosahexaenoate that are precursors of the anti-inflammatory lipid mediators, resolvins (By similarity). During the resolution phase of acute inflammation drives docosahexaenoate-derived resolvin D1 synthesis, which suppresses dendritic cell activation and T-helper 1 immune response (By similarity). May act in an autocrine and paracrine manner (By similarity). Via a mechanism independent of its catalytic activity, promotes differentiation of regulatory T cells (Tregs) and participates in the maintenance of immune tolerance (By similarity). May contribute to lipid remodeling of cellular membranes and generation of lipid mediators involved in pathogen clearance. Displays bactericidal activity against Gram-positive bacteria by directly hydrolyzing phospholipids of the bacterial membrane (By similarity)

The "PLA2G2D Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PLA2G2D comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets